2,5-Dimethoxy-4-benzylamphetamine

2,5-Dimethoxy-4-benzylamphetamine is a serotonin 5-HT₂ receptor modulator of the amphetamine and DOx families. It is the DOx derivative with a benzyl ring at the 4 position.
The drug's affinities for the human serotonin 5-HT₂ receptors have been found to be 0.40nM for the serotonin 5-HT_2A receptor, 24.5 to 35.0nM for the serotonin 5-HT_2B receptor, and 1.0nM for the serotonin 5-HT_2C receptor. Its affinities for the serotonin 5-HT₂ receptors are very similar to those of DOB. The drug has been assessed and found to act as a silent antagonist of the serotonin 5-HT_2B receptor. In rodent drug discrimination tests, DOBz neither antagonized nor generalized to the stimulus of DOM. Higher doses produced behavioral disruption however.
DOBz was first described in the scientific literature by Richard Glennon and colleagues in 1989. It is a controlled substance in Canada under phenethylamine blanket-ban language.